BOSTON, June 17, 2020 –  Dewpoint Therapeutics, the biomolecular condensates company, has announced the appointments of Olivier Brandicourt and Jürgen Eckhardt to […]

Dewpoint congratulates its co-founder, Tony Hyman, who was this week elected to the National Academy of Sciences in honor of his […]

Dewpoint congratulates its co-founder Tony Hyman, for receiving the NOMIS Foundation’s Distinguished Scientist and Scholar Award.  The award recognises outstanding contributions […]

Dewpoint Therapeutics co-founder Anthony Hyman will share the 2020 Wiley Prize in Biomedical Sciences for his foundational work on biomolecular […]

The announcement of Dewpoint Therapeutics $100M partnership Bayer to research new treatments for cardiovascular and gynecological diseases has received significant […]

BERLIN / BOSTON, November 14, 2019 – Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, […]

Dewpoint congratulates our scientific founder, Richard Young, on being named to the National Academy of Medicine.

BERLIN / BOSTON, September 23, 2019 –  Rounding out a year of tremendous growth on two continents, Dewpoint Therapeutics, the biomolecular condensates company, has […]

The announcement of the launch of Dewpoint Therapeutics, with $60 Million Series A funding has received significant attention from media […]

CAMBRIDGE, Mass. January 30, 2019 – Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched […]

Isaac Klein, M.D., Ph.D. How did the discovery of condensates transform our understanding of the cell? We thought the cell […]